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Objective: Asthma is a major cause of morbidity and mortality and is associated with 
significant economic burden worldwide. The objectives of this study were to map current 
resource use associated with the disease management and to estimate the annual direct 
and indirect costs per adult patient with asthma.
Methods: A Delphi panel with seven leading pulmonologists was conducted. A semi­
structured questionnaire was developed to elicit data on resource use and treatment 
patterns. Unit costs from official, published sources were subsequently assigned to 
resource use to estimate direct medical costs. Indirect costs were estimated as number 
of work loss days. Cost base year was 2015, and the perspective adopted was that of 
the National Organization of Health Care Services Provision, as well as the societal.
results: Patients with asthma are mainly managed by pulmonologists (71.4%) and 
secondarily by general practitioners and internists (28.6%). The annual cost of managing 
exacerbations was estimated at €273.1, while maintenance costs were estimated at 
€1,100.2 per year. Total costs of managing asthma per patient per year were estimated 
at €2,281.8, 64.4% of which represented direct medical costs. Of the direct costs, phar­
maceutical treatment was the key driver, accounting for 63.9 and 41.2% of direct and 
total costs, respectively. Direct non­medical costs (patient travel and waiting time) were 
estimated at €152.3. Indirect costs accounted for 28.9% of total costs.
conclusion: Asthma is a chronic condition, the management of which constrains the 
already limited Greek health care resources. The increasing prevalence of the disease 
raises concerns as it could translate per patient costs into a significant burden for the 
Greek health care system. Thus, the prevention, self­management, and improved quality 
of care for asthma should find a place in the health policy agenda in Greece.
Keywords: asthma, burden, direct cost, indirect cost, greece
2Souliotis et al. Cost of Asthma in Greece
Frontiers in Public Health | www.frontiersin.org April 2017 | Volume 5 | Article 67
inTrODUcTiOn
Asthma is an obstructive airway disorder and one of the most 
common chronic diseases in the world (1, 2). It has been esti-
mated to affect 300 million individuals worldwide (3), and about 
30 million children and adults younger than 45 years have asthma 
in Europe (4). In USA, asthma prevalence increased from 7.3% in 
2001 to 8.4% in 2010 (5), while in Greece, it has been estimated 
at 8.6% of the general population (6). Asthma is a global public 
health problem, and the World Health Organization reports that 
it affects all countries regardless of level of development (7).
Although asthma is associated with low mortality rates (8), it 
is a major cause of morbidity and is associated with significant 
economic burden. The number of years lived with disability 
worldwide was estimated at 15.9 million in 2015 (9). The eco-
nomic cost of asthma is considerable in terms of both direct 
medical (hospitalization and pharmaceutical care) and indirect 
costs (productivity losses) (1). A recent review showed that 
annual per patient costs in the published literature varied from 
less than US$150 in Abu Dhabi to more than US$3,000 in USA 
(10). Indirect costs per year have been estimated at US$426 and 
US$1,154 per patient in USA and Europe, respectively (11, 12).
Despite the size of asthma prevalence in Greece, there is scarce 
evidence quantifying the economic burden of the disease. In 
the literature, only one study, dating back to 1997, was identi-
fied, which aimed at estimating both direct and indirect costs 
associated with the management of the disease (13). The study 
reported total direct medical costs of 15.5 billion drachmas 
(approximately €44 million in 1997 prices) and indirect costs 
of 14.2 billion drachmas (approximately €41.7 million in 1997 
prices). The study also reported 800,000 asthma-attributed work 
days lost (13). Since that publication, direct and indirect costs in 
the country have not been adequately explored, despite changing 
disease management strategies. The objective of this study was to 
provide recent estimates of the direct and indirect costs of asthma 
management in adult patients in Greece, by experts mapping cur-
rent resource use associated with disease management.
MaTerials anD MeThODs
A Delphi panel with seven leading pulmonologists, members of 
the Asthma Working Group of the Hellenic Thoracic Society, was 
conducted. The members of the panel were selected on the basis 
of experience (≥15 years) and number of patients with asthma 
they currently manage (≥50 per month) and represented all 
settings of health care provision in Greece (public and private 
hospitals, University hospitals, and private physician office). All 
experts were selected from the Attica Health Care District, cur-
rently covering almost half the Greek population, and were asked 
to provide their opinion on real-world data, i.e., to describe how 
asthma is currently being managed in the country.
To map local treatment patterns and resource use for the 
management of asthma, a semistructured questionnaire was 
developed with input from the international literature, which 
was validated by clinical experts. The questionnaire consisted 
of questions on direct medical costs (pharmaceutical, medical, 
hospital care, as well as lab and functional/imaging tests), direct 
non-medical costs (patient travel and waiting time to receive 
medical care), and indirect costs (non-paid caregivers’ time and 
work loss days due to sick leave prescribed by the physician). 
The use of additional resources (oxygen therapy and nebulizers 
at home) was also recorded. All resource use components were 
collected for the maintenance phase and exacerbations.
The questionnaire completion method was the Delphi 
technique, which provides mean values for each parameter by 
achieving convergence of opinion through multiple rounds of 
completion (14). The process was conducted between October 
2015 and January 2016, and consensus was reached during the 
second round of completion.
Total costs were subsequently calculated by assigning unit 
costs on resource use data collected via the expert panel. Direct 
medical costs were estimated from the perspective of the National 
Organization of Health Care Services Provision (EOPYY), which 
currently covers more than 90% of the Greek population (15). 
The cost of pharmaceutical treatment was estimated based on 
reimbursement prices (16); hospitalization costs were based on 
the diagnosis-related groups (DRGs) (17); intensive care unit 
(ICU) costs were based on the Decree published by the Ministry 
of Health (18); lab and imaging test costs were estimated with 
prices reimbursed by EOPYY (19); and the cost of additional 
resources was calculated based on the Unified Regulation for 
Health Care Benefits (EKPY) (20). The cost base year was 
2015. Indirect costs were estimated based on Organization for 
Economic Cooperation and Development data for Greece’s per 
capita gross domestic product (GDP), projected to 2015 based 
on historical average annual growth rate (2008–2014) (21). All 
cost estimates refer to the average patient, i.e., have been weighted 
with the probability of use of each resource item. In addition, 
the average waiting time has been weighted with the respective 
percentages of patients visiting physicians’ private offices and 
hospital outpatient clinics.
resUlTs
Patients with asthma are mainly managed by pulmonologists 
(71.4%) and secondarily by general practitioners (GPs) and 
internists (jointly representing 28.6%). During the maintenance 
phase, the health care settings that patients most frequently visit 
are hospital outpatient clinics (49.1%) and physician’s private 
offices (45.7%), while 5.2% receive treatment at home. During 
exacerbations, visits at home are slightly increased (8.8%), while 
29% of the patients also visit the hospital emergency rooms 
(ERs) (Table 1). Laboratory tests during both exacerbations and 
maintenance phase include complete blood count, biochemi-
cal tests, and urine analyses. Imaging tests include spirometry, 
electrocardiogram, chest X-ray, and computerized tomography. 
The frequency and percentage of patients undergoing each test 
per exacerbation and during the maintenance phase, as well as 
the unit costs per test, are presented in Table 1.
The breakdown of the total direct medical costs into its com-
ponents is illustrated in Table 2. During the maintenance phase, 
the largest cost component is pharmaceutical treatment, which 
accounts for more than 80% of total maintenance cost. The Delphi 
panel results indicate that the majority of patients (81%) receive 
a combination of inhaled corticosteroids and long-acting beta 
agonists, while 9% receive ICS monotherapy. Thirty-six percent 





Private physician 0.9 51.8
Hospital outpatient clinic 2.0 48.2
Number of visits per year 14.3
Daily (hourly) wage rate (€) 57.4 (7.2)
Patient time cost (€) 152.3
Table 2 | annual per patient costs during exacerbations and 
maintenance phase (€).
annual costs associated 
with the management of 
exacerbationsa (% of total)
annual costs of the 
maintenance phase 
(% of total)
Pharmaceutical treatment 22.9 (8.4) 916.9 (83.3)
Medical treatment 10.3 (3.8) 65.1 (5.9)
Hospitalization 84.2 (30.8) 33.2 (3.0)
ICU 71.0 (26.0) –
Lab tests 21.3 (7.8) 27.0 (2.5)
Functional/imaging tests 63.4 (23.2) 58.0 (5.3)
Total 273.1 (100.0) 1,100.2 (100.0)
ICU, intensive care unit.
aBased on the mean number of exacerbations per year (1.6).
Numbers have been rounded to the nearest euro, thus percentages might not  
sum up to 100%.
Table 1 | resource use and unit costs.
exacerbations Maintenance phase Unit cost (€)
% of patients Frequency per exacerbation % of patients Frequency per year
A&Eb 29.0 1.1 – – –
Physician visits
Visit to hospital outpatient clinicsb 45.3 1.2 49.1 14.3 –
Visit to physician’s private office 45.9 1.4 45.7 10
Physician’s visit at homeb 8.8 1.2 5.5 –
laboratory tests
CBC 68.0 1.2 21.0 1.0 2.9
Biochemical testsa 42.0 1.2 15.0 0.8 21.7
Allergy blood testing (IgE + RAST) – – 70.0 1.0 23.8
Urine analysis 2.0 0.1 – – 1.8
Functional/imaging tests
Spirometry 64.0 1.2 94.0 1.3 44.0
Electrocardiogram 20.0 0.7 10.0 0.9 4.1
Chest CT 12.0 0.7 12.0 0.6 45.0
Chest X­ray 37.0 1.2 23.0 0.7 4.1
CBC, complete blood count; IgE, immunoglobulin E; RAST, radioallergosorbent test; CT, computerized tomography.
aIncluding urea, creatinine, SGOT-SGPT-K-Na-Ca, and LDH.
bNot reimbursed by EOPYY.
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of all patients receive montelukast on top and irrespective of 
other pharmaceutical treatment. Contrary to the maintenance 
phase, during the exacerbation phase, pharmaceutical treatment 
accounts for a considerably smaller proportion (i.e., eightfold 
less) of total direct medical costs. The key cost driver is hospital 
and ICU admissions, which jointly account for more than half of 
the total exacerbation costs (Table 2).
The Delphi panel reported that only 10% of patients require 
hospitalization during the exacerbation phase and 40% of those 
hospitalized fall under the DRG code A29M (Bronchitis and 
asthma with comorbidities and/or complications), with an aver-
age length of stay (LOS) of 4 days and a cost of €792. The remaining 
60% of patients is hospitalized under DRG code A29X (Bronchitis 
and asthma without comorbidities and/or complications), with 
an average LOS of 2 days and mean cost of €361. Of the patients 
hospitalized, 3.8% requires hospitalization in an ICU, with a LOS 
of 5.8 days and an additional cost of €1,167 per patient. Hence, the 
average cost per exacerbation—weighted with the probability of 
requiring hospitalization in an ICU—is estimated at €44.4, while 
the mean number of asthma exacerbations per patient is reported 
to be 1.6 per year. The cost of medical treatment appears to be 
very low as physician visits are reimbursed by EOPYY at €10 (22), 
although at private practice, out-of-pocket payments per visit 
may vary. Moreover, the management of asthma does not require 
significant use of additional resources. In particular, only 4.2 and 
16.6% of asthma patients require nebulizer and oxygen therapy 
at home, respectively, with the average cost of these resources 
estimated at €96.6 per year.
The average patient time for medical follow-up and prescrip-
tion-related visits to physicians, including travel and waiting 
time, ranged from 0.9 to 2 h for the private office and the hospital 
outpatient clinics, respectively (Table  3). Given that patients 
visit their physician approximately 1.2 times per month during 
the maintenance phase, the total number of medical follow-up 
visits was estimated at 14.3 per year, and thus, the mean patient 
time was estimated to range between 12.9 and 29 h per year. The 
mean annual cost of patient time (based on the mean daily wage 
rate and weighted for the percentage of patients per health care 
setting) was €152.3. The average number of work loss days per 
year was estimated at 10.5 (Table 4). In addition, approximately 
2.7% of patients receive assistance from relatives and/or friends 
for their daily activities. This assistance results in caregivers’ time 
Table 5 | Total per patient costs (€).
annual cost % of total cost
Direct medical costa 1,469.8 64.4
Pharmaceutical treatment 939.8 41.2
Medical treatment 75.4 3.3
Hospitalization and ICU 188.3 8.3
Lab and functional/imaging tests 169.7 7.4
Costs of additional resources 96.6 4.2
Direct non-medical cost 152.3 6.7
Cost of patients’ time 152.3 6.7
Productivity losses 659.7 28.9
Cost of work loss days 602.6 26.4
Cost of non­paid caregivers’ time 57.1 2.5
Total cost 2,281.8 100
ICU, intensive care unit.
aDirect medical costs reflect both maintenance phase and exacerbation-related costs.
Numbers have been rounded to the nearest euro.
Table 4 | indirect costs: cost of work loss days and cost of caregivers’ 
time per year.
Daily (hourly) wage rate (€) 57.4 (7.2)
Work loss days due to asthma per yeara 10.5
cost of work loss days (€) 602.6
Percentage of patients requiring assistance from family/friends 2.7
Mean number of days per week 2.1
Mean number of hours per day 3.6
Percentage of caregivers who are economically active 75%
caregiver cost (€) 57.1
aNumber of days of sick leave prescribed by the physicians.
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of approximately 2.1 h per day, 3.6 days per week with 75% of the 
caregivers being economically active.
Table 5 illustrates the estimated sum and breakdown of the 
aforementioned direct medical, direct non-medical, and indirect 
costs. Direct non-medical and indirect costs account for 37% of 
total asthma-related costs.
DiscUssiOn
This study explored the direct and indirect costs of asthma in 
Greece. Annual per patient costs were estimated at €2,282, with 
direct (medical and non-medical) and indirect costs account-
ing for 71 and 29% of total costs, respectively. The key driver 
of direct costs was pharmaceutical treatment (63.9%), whereas 
hospitalization (including admission to the ICU) was responsible 
for 8.3% of direct costs.
These findings are consistent with the international lit-
erature. Study findings suggest that medication costs are the 
largest cost component of direct costs in North America and 
Europe, ranging from 51% in USA to 68% in Canada and in 
Europe from 45% in Spain to 84% in Germany (11, 12, 23). 
On the other hand, there is evidence supporting a downward 
trend in rates and costs associated with hospitalization (23–25). 
This is attributed to the effective medication usage during the 
maintenance phase, resulting in fewer exacerbations and thus 
hospitalizations (26).
This trend along with the introduction of usage of LABA/
ICS combinations during the maintenance phase could—at least 
partly—explain the discrepancies between our findings and the 
previous study conducted by Matsaganis et al. within the Greek 
health care setting (13). The latter had shown much lower than 
the current estimate costs for pharmaceutical care (35% of direct 
costs) and a much higher share of hospitalization costs (28%). 
However, that study is quite old, and treatment patterns, as 
well as major cost centers in the management of asthma, have 
significantly changed since then, not only in Greece but also 
globally. Over the 20-year gap between the two studies, many 
new medications have received marketing authorization for the 
management of asthma (mainly LABA/ICS), changing the treat-
ment landscape and leading both to higher costs and improved 
effectiveness, which reduce the need for hospitalization. Recent 
findings suggest that pharmaceutical costs have been increasing 
in USA and Canada (10). In particular, in USA, medication costs 
have increased by 49% between 2000 and 2009 (24), while from 
2001 to 2009, ER visits and hospitalization rates per 100 asthma 
patients remained stable (5).
Indirect costs estimated in our study account for almost one-
third of total costs, and although they constitute a significant cost 
component, they are still lower than the respective estimate in 
the Matsaganis et al.’s study (48%) (13). This could be attributed 
mainly to the fact that in the latter study, work loss days were 
evaluated at the cost of labor, which was much higher at that time. 
Since Greece entered the era of economic crisis in 2008, the cost 
of labor and per capita GDP have been following a decreasing 
trend, leading to lower estimates of productivity losses.
Another interesting finding of this study is that contrary to 
what would be expected, the costs of exacerbations appear to be 
lower than the maintenance phase. This could be explained by 
the method of data collection and the structure of the health care 
system in Greece. Delphi panel data largely reflect the perceptions 
of physicians who typically monitor patients during the mainte-
nance phase, whereas in the exacerbation phase, a considerable 
number of patients (almost 30%) seek care in the ERs of hospitals. 
In addition, there is evidence in the literature that asthma control 
before an exacerbation plays a role in the resource use and cost 
during exacerbations, with higher exacerbation costs in uncon-
trolled asthma patients (27). Thus, patients currently being man-
aged by pulmonologists could be better controlled, thus reporting 
lower resource use during exacerbations.
Our study has certain limitations. First, all experts participat-
ing in the Delphi panel came from the Attica Health Care District; 
thus, it could be argued that results are not representative and 
could not be extrapolated to the national level, since health ser-
vices in Greece are unequally distributed and patient pathways in 
rural areas may differ from those in Attica. However, Attica is the 
largest Health Care District in the country, covering almost half 
of the Greek population. Moreover, experts were selected as key 
opinion leaders, having the ability to describe the clinical practice 
in the country. They were asked throughout the questionnaire 
completion process to provide input regarding real-world knowl-
edge, i.e., their opinion on how asthma is managed across the 
country and not only in their setting and district.
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In addition, there are certain aspects of asthma-related costs 
that have not been explored in this study, such as social care, 
pulmonary rehabilitation, presenteeism, productivity loss due to 
early retirement, and shorter life expectancy. Although social care 
and pulmonary rehabilitation are very limited within the Greek 
health care setting and it would be expected to have a negligible 
impact on costs, the other cost components ought to be explored 
in future studies.
Our study is also based on expert opinion rather than 
patient level data; however, the Delphi technique is a widely 
used and accepted method for achieving convergence and is 
well recognized as a qualitative technique for data elicitation on 
resource use (14). In addition, the Delphi panel only included 
pulmonologists, although GPs also have an important role 
in the disease management, and did not include patients who 
could have provided a better estimate of non-medical direct 
(e.g., travel costs) and indirect costs (e.g., productivity loss) of 
asthma management. Therefore, the results of this study could 
be considered as a first step toward providing updated estimates 
of asthma management costs and should be supplemented by 
additional studies, exploring costs through patient surveys or 
case vignettes (28).
Overall, this study aimed at covering a literature gap of 
20 years by capturing resource use and treatment patterns and 
updating estimates of direct and indirect cost associated with 
the management of asthma, through a validated process. Per 
patient asthma costs are high, and the increasing prevalence 
of the disease translates per patient costs into a significant 
burden for the Greek health care system. Therefore, asthma 
should be recognized as a  priority disorder in government 
strategies and planning, and results of this study can feed into 
the discussions around cost rationalization policies in the field 
of health care.
cOnclUsiOn
Asthma is a chronic condition, the management of which con-
strains the already limited Greek health care resources. The 
increasing prevalence of the disease raises concerns as it could 
translate per patient costs into a significant burden for the Greek 
health care system. Thus, the prevention, self-management, and 
improved quality of care for asthma should find a place in the 
health policy agenda in Greece.
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